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Abstract 29	
Study hypothesis: Myometrial explants represent a superior model for the study of human 30	
myometrial progesterone (P4) signalling in parturition.  31	
Study finding: The transcriptome of myometrial explants closely resembles the in vivo 32	
condition and the anti-inflammatory action of P4 is not lost with labour onset.  33	
What is known already: Circulating P4 levels decline before the onset of parturition in most 34	
animals, but not in humans. This has led to the suggestion that there is a functional 35	
withdrawal of P4 action at the myometrial level prior to labour onset. However, to date, no 36	
evidence of a loss of P4 function has been provided, with studies hampered by a lack of a 37	
physiologically relevant model. 38	
Study design, samples/materials, methods: Myometrial biopsies obtained at Caesarean 39	
section were dissected into explants after a portion was immediately snap-frozen (t=0). 40	
Microarray analysis was used to compare the t=0 transcriptome to paired  (i) explants, (ii) 41	
primary myometrial cell cultures as well as (iii) the hTERT myometrial cell line. Western 42	
blotting and chemokine/cytokine assays were used to study P4 signaling in myometrial 43	
explants.  44	
Main results and the role of chance: Transcriptomic comparison of t=0 to the three models 45	
demonstrated that explants more closely resemble the in vivo status. At the protein level, 46	
explants maintain both P4 receptor (PR) and glucocorticoid receptor (GR) levels versus t=0 47	
whereas cells only maintain GR levels. Additionally, treatment with 1µM P4 led to a 48	
reduction in IL-1β-driven cyclooxygenase-2 in explants but not in cells.  P4 signalling in 49	
explants was PR-mediated and associated with a repression of p65 and c-Jun phosphorylation. 50	
Furthermore, the anti-inflammatory action of P4 was maintained after labour onset. 51	
Limitations/reasons for caution: There is evidence of basal inflammation in the myometrial 52	
explant model.  53	
Wider implications of the findings: Myometrial explants constitute a novel model to study 54	
P4 signalling in the myometrium and can be used to further elucidate the mechanisms of 55	
functional P4 withdrawal in human labour.  56	
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Introduction 84	
The seminal work of Csapo and Frydman demonstrated that progesterone (P4) is essential for 85	
human pregnancy, the former showing that P4 is responsible for the maintenance of early 86	
pregnancy and that its removal results in miscarriage (Csapo et al. , 1973) and the latter, that 87	
blocking P4 can result in the onset of labour (Frydman et al. , 1991). However, while in most 88	
animals labour follows a precipitous fall in peripheral P4 levels, no such fall occurs in 89	
humans and non-human primates. This has led to the concept of a myometrial functional P4 90	
withdrawal and several theories have been proposed to explain it. The most widely accepted 91	
is that there is a change in the balance of expression of the P4 receptor (PR), which is 92	
comprised of 2 main isoforms: PR-B, which mediates the effects of P4, and PR-A, which 93	
antagonises PR-B-mediated P4 signalling, but is also transcriptionally active in its own right. 94	
An increase in the PR-A:PR-B ratio at the time of labour onset has been demonstrated in 95	
myometrial samples obtained at the time of labour at the mRNA and protein level (Merlino et 96	
al. , 2007, Mesiano et al. , 2002). Furthermore, in PR-A-dominant myometrial cells, P4 97	
enhances pro-inflammatory gene expression (Tan et al. , 2012). Another theory suggests that 98	
uterine quiescence is maintained throughout pregnancy by a PR-mediated inhibition of the 99	
actions of the pro-inflammatory transcription factor NF-κB (Kalkhoven et al. , 1996), 100	
possibly via the NF-κB inhibitor IκBα (Hardy et al. , 2006), but that with the onset of labour, 101	
inflammation-induced NF-κB represses PR action bringing about a uterine switch to a 102	
contractile phenotype (Allport et al. , 2001). A third theory suggests that changes to PR co-103	
regulator expression may cause labour onset (Condon et al. , 2003). All three mechanisms 104	
have the common end result of a loss of myometrial sensitivity to P4 action and the onset of 105	
labour. Efforts to use a mouse model to study this question have been limited, as PR-A 106	
knock-out mice are infertile, while no apparent change in ovarian and uterine function was 107	
observed in PR-B knock-out mice (Mulac-Jericevic et al. , 2003, Mulac-Jericevic et al. , 108	
2000).   109	
P4 supplementation has been shown to reduce the risk of preterm labour in high-risk singleton 110	
pregnancies (da Fonseca et al. , 2003, Meis et al. , 2003). The mechanism involved is 111	
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uncertain, but since labour is widely accepted to be an inflammatory event (Bollapragada et 112	
al. , 2009), it is assumed that P4 acts to maintain pregnancy by repressing inflammation. On 113	
that basis, the ability of P4 to repress inflammation-induced cyclooxygenase-2 (COX-2) 114	
expression has been widely used as a model of P4 action. COX-2 expression is driven by the 115	
inflammatory transcription factors NF-κB and activator protein-1 (AP-1) (Khanjani et al. , 116	
2011, Khanjani et al. , 2012, Lim and Lappas, 2014, Soloff et al. , 2004). Several studies have 117	
investigated whether P4 inhibits NF-κB and AP-1 activation to repress COX-2 expression, 118	
but these have typically been performed in primary cell cultures or cell lines and have 119	
involved the over-expression of PR, NF-κB and/or AP-1 (Bamberger et al. , 1996, Hardy et 120	
al., 2006, Kalkhoven et al., 1996). Primary cultures of uterine smooth muscle cells 121	
(henceforth referred to as primary cells) have been shown to maintain structural and 122	
functional characteristics (Lee et al. , 2012, Mosher et al. , 2013), but are possibly not an 123	
optimal model for the study of P4 action as high doses of P4 (10µM) are required to bring 124	
about a reduction in IL-1β-driven COX-2 (Lei et al. , 2012). Previous work by our group 125	
using this model has demonstrated that P4 signals via the glucocorticoid receptor (GR) to 126	
reduce COX-2 (Lei et al., 2012) via MAPK phosphatase-1 (MKP-1) (Lei et al. , 2015), 127	
however, this may be because PR levels are lower in primary cells compared to snap-frozen 128	
tissue.  129	
In order to overcome the limitations of myometrial cell culture, we have developed an 130	
explant-based model for the ex vivo study of myometrial function. We compared the 131	
transcriptome of tissue snap frozen at the time of Caesarean section (t=0) to myometrial 132	
explants, primary cells and the hTERT myometrial cell line.  We subsequently compared PR 133	
protein levels in t=0, myometrial explants and primary cells before using this system to study 134	
P4 action in myometrial samples before and after the onset of labour to test the hypothesis 135	
that a functional withdrawal of P4 action occurs with the onset of labour. 136	
 137	
Methods 138	
Ethical approval 139	
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The Brompton and Harefield Research Ethics Committee approved this project. 140	
 141	
Myometrial biopsies  142	
Myometrial biopsies were obtained from women at term (≥37 weeks) following informed 143	
consent at the time of planned or emergency Caesarean section. Women with multiple 144	
pregnancy, gestational diabetes mellitus, pre-eclampsia and obstetric cholestasis were 145	
excluded. In addition, labouring women were recruited to the study if labouring 146	
spontaneously and requiring an emergency Caesarean section due to fetal distress or a breech 147	
presentation. Cervical dilatation was used to categorise labour into early (≤3cm) or 148	
established (>3cm). Biopsies were collected into sterile universal bottles containing 149	
phosphate-buffered saline (PBS) and were processed immediately. Samples used were as 150	
follows: term no-labour (TNL): n=35; term early labour (TEaL): n=8 and term established 151	
labour (TEsL): n=8. 152	
 153	
Explant Culture 154	
Biopsies were dissected into 3x3x3mm3 pieces (explants) and placed in Dulbecco’s Modified 155	
Eagle Medium (DMEM) (Sigma-Aldrich Ltd., Dorset, UK) supplemented with penicillin-156	
streptomycin (Sigma-Aldrich Ltd.) or immediately snap-frozen in liquid nitrogen (t=0). 157	
Depending on the experimental protocol, explants were either untreated or immediately 158	
treated for 6 hours with vehicle control (ethanol ± DMSO), progesterone (100nM, 500nM, 159	
1µM, 5µM or 10µM; Sigma-Aldrich Ltd.), dexamethasone (1µM; Sigma-Aldrich Ltd.), 160	
mifepristone (RU486, 1µM; Sigma-Aldrich Ltd.) or onapristone (ZK299, 1µM; Arno 161	
Therapeutics, Flemington, NJ, USA). They were subsequently treated for a further 24 hours 162	
with IL-1β (1, 10, 20, 50 or 100ng/mL; Sigma-Aldrich Ltd.), at which point all tissues were 163	
snap-frozen in liquid nitrogen and stored at -80°C. The media in which explants were cultured 164	
were also stored at -80°C. 165	
 166	
Cell Culture 167	
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Biopsies were digested in a mixture of collagenases as previously described (Sooranna et al. , 168	
2004) and passaged by trypsinization in 0.25% trypsin containing 0.02% EDTA (Sigma-169	
Aldrich Ltd.) when confluent. Once confluent at passage 4, cells were serum-starved 170	
overnight in 1% charcoal and dextran-stripped fetal calf serum (1% DCC) supplemented with 171	
penicillin-streptomycin. They were then cultured and treated using the same protocol as 172	
explant cultures and were placed at -80°C once the experiment was completed.  Supernatants 173	
were stored at -80°C.  174	
The myometrial hTERT cell line was cultured in the same conditions as primary cells with 175	
overnight serum-starving once cells reached confluence. Once thawed, cells were not 176	
passaged beyond passage 5.  177	
 178	
RNA extraction 179	
Total RNA was extracted using a Trizol® Plus RNA Purification kit (Thermo Fisher 180	
Scientific, Ambion, Abgene Ltd., West Sussex, UK) with on-column DNase treatment prior 181	
to elution, all as per the manufacturer’s protocol. Bead homogenization in Precellys® tubes 182	
(Stretton Scientific Ltd., Derbyshire, UK) was used for tissue lysis with two 20 second cycles 183	
at 5000rpm; cells were lysed directly with Trizol® added to the culture plate. The 184	
concentration and purity of RNA was determined by spectrophotometry and integrity was 185	
confirmed using an Agilent 2100 Bioanalyzer with an RNA 6000 Nano Kit (Agilent 186	
Technologies, Palo Alto, CA, USA).  187	
 188	
Microarray Analysis 189	
Whole-genome transcriptome analysis was conducted by hybridizing 6 biological samples of 190	
total RNA per condition to Affymetrix Human Gene 2.1 ST Arrays Strips (Affymetrix, Santa 191	
Clara, CA, USA). A minimum RIN score of 8 was used as cut off for inclusion in the 192	
microarray analysis. All steps were conducted at the Nottingham Arabidopsis Stock Centre. 193	
Gene expression data were analysed using Partek Genomics Suite 6.6 software (Partek 194	
Incorporated, St. Louis, USA). The raw CEL files were normalised using the RMA 195	
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background correction with quantile normalization, log base 2 transformation and mean 196	
probe-set summarization with adjustment for GC content. Differentially expressed genes 197	
(DEG) were identified by a two-way ANOVA, and p-values were adjusted using the FDR 198	
(false-discovery rate) method to correct for multiple comparisons. DEG were considered 199	
significant if p-value was £ 0.05 at a fold change (FC) of > 2 with FDR <0.5. 200	
 201	
Quantitative RT-PCR 202	
Following quantification, 1µg RNA was reverse transcribed with oligo dT random primers 203	
using MuLV reverse transcriptase (Life Technologies Ltd., Paisley, UK). Primer sets were 204	
designed and obtained from Invitrogen (Table I). Quantitative PCR was performed using 205	
SYBR Green (Roche Diagnostics Ltd., West Sussex, UK) using the previously described 206	
cycling protocol (Lei et al., 2015) and amplicon yield was monitored during cycling in a 207	
RotorGene Sequence Detector (Qiagen Ltd., West Sussex, UK). The abundance of mRNA for 208	
sequences of interest were expressed relative to the constitutively expressed GAPDH. 209	
 210	
Protein Extraction and Western Blotting 211	
Protein was extracted from explants using bead homogenization in pre-cooled Precellys® 212	
tubes (Stretton Scientific Ltd.) containing lysis buffer (New England Biolabs, 213	
Hertfordshire,UK) supplemented with protease (Roche Diagnostics Ltd.) and phosphatase 214	
inhibitors (Thermo Fisher Scientific, Abgene Ltd., Epsom, UK).  Tissues were immediately 215	
homogenised by mechanical disruption by two 20 second cycles at 5000rpm. Protein from 216	
cells was extracted via direct lysis using the same lysis buffer mixture as for explants. The 217	
supernatant was separated from tissue debris by centrifugation at 13000rpm for 10 minutes at 218	
4°C. Protein concentrations were determined by DC protein assay (Bio-Rad Labouratories 219	
Ltd., Hertfordshire, UK) and bovine serum albumin (Sigma-Aldrich Ltd.) was used for 220	
reference standards.  221	
Samples in NuPAGE® LDS Sample Buffer (Life Technologies Ltd.) were denatured at 75°C 222	
for 10 minutes and 20µg of total protein for each sample was electrophoresed through a 4-223	
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20% polyacrylamide gel (Bio-Rad Labouratories Ltd.). Transfer was carried out onto a 224	
polyvinylidene fluoride membrane (Bio-Rad Labouratories Ltd.) using the Trans-Blot® Turbo 225	
Transfer system (Bio-Rad Labouratories Ltd.), followed by blocking in 5% nonfat dried milk 226	
powder (AppliChem GmbH, Germany) dissolved in 0.1% Tween-Tris buffered saline (TBS-227	
T) for 1 hour at room temperature. The membrane was incubated overnight at 4°C with 228	
primary antibody followed by incubation for 2 hours at room temperature with secondary 229	
antibody (Table II). Clarity Western ECL substrate (Bio-Rad Labouratories Ltd.) was used for 230	
detection. Protein band size was determined using Precision Plus Protein Standards ladder 231	
(Bio-Rad Labouratories Ltd.). All protein abundance data were expressed relative to the 232	
amount of constitutively expressed GAPDH after 1 hour incubation at room temperature 233	
(Table II). 234	
 235	
Chemokine/Cytokine Assays 236	
Human Bio-Plex© ProTM chemokine/cytokine assays (Bio-Rad Labouratories Ltd.) were used 237	
to measure the concentrations of IL-1α, IL-1β, IL-6, IL-8, CCL2, CCL5, CCL11, CCL20, 238	
ICAM and LIF in explant culture media. These were performed according to the 239	
manufacturer’s instructions and were read using a Bio-Plex© 200 reader and Bio-Plex 240	
Manager ©  v6.1 software  (Bio-Rad Labouratories Ltd.). Data were normalised to tissue 241	
weights. 242	
 243	
Statistical analysis 244	
Statistical analysis was performed using Graphpad Prism v5.0 (Graphpad Software Inc., La 245	
Jolla, CA, USA). Normality was determined via a Kolmogorov-Smirnov test for up to 6 246	
replicates or a Shapiro Wilks test for more than 6 replicates. Normally distributed data were 247	
subsequently analysed using a paired t test for the comparison of 2 groups or an ANOVA 248	
followed by Bonferroni’s multiple comparison test post hoc testing for three groups or more. 249	
Data that were not normally distributed were analysed using a Wilcoxon matched pairs test or 250	
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a Kruskal-Wallis followed by Dunn’s multiple comparisons post hoc testing for three groups 251	
or more. p<0.05 was considered statistically significant. 252	
 253	
Results 254	
The myometrial explant transcriptome closely resembles the in vivo status 255	
Biopsies obtained from non-labouring women at elective Caesarean section at term, were 256	
divided into 3: (i) dissected and immediately snap frozen (t=0), (ii) dissected for myometrial 257	
explants and (iii) processed for primary cell culture.  Explants, primary cells at passage 4 (the 258	
typical passage our group uses for experiments) and the hTERT cell line were cultured for a 259	
period of 30 hours without treatment. Transcriptomic analysis via microarray demonstrated 260	
that explants most closely resemble t=0 (Fig. 1A). Upon direct comparison between explants 261	
and t=0, 1444 genes varied significantly whereas the corresponding number for primary cells 262	
was 3840 and for hTERT 4603 (Fig. 1B). 555 genes varied commonly upon comparing all 3 263	
groups to t=0 with gene ontology analysis demonstrating higher enrichment scores for 264	
functions including ‘immune response’, ‘inflammatory response’ and ‘leukocyte migration’ 265	
(Suppl. 1). Furthermore, explants shared 119 genes exclusively with primary cells and 137 266	
genes with hTERT; the equivalent figure for the primary cells and hTERT overlap was 2111 267	
(Fig. 1B). Of the 633 genes uniquely upregulated in the explant group, the most common 268	
gene ontology groups pertained to glucose metabolism including ‘glycolysis’, 269	
‘gluconeogenesis’ and ‘glucose metabolic process’ (Suppl. Table II). Overall, the degree of 270	
variability on comparing t=0 to each of the 3 groups was least for explants (Fig. 1C) followed 271	
by primary cells (Fig. 1D) and hTERT (Fig.1E).  272	
A second set of biopsies and hTERT cultures were used to validate the microarray results via 273	
quantitative RT-PCR. Microarray trends were preserved for a panel of genes of interest 274	
including those associated with reproductive function (PTGS2, OXTR, PGR, GJA1) and 275	
smooth muscle phenotype (ACTA2, MYLK) (Table III). Overall, 15 genes of interest were 276	
chosen for validation of microarray results with 3 comparisons performed per gene (explants 277	
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versus t=0, primary cells versus t=0, hTERT versus t=0); microarray and RT-PCR data 278	
followed the same trend in 39 of 45 cases (86.7%).   279	
 280	
Nuclear receptor levels 281	
Subsequent experiments focused on comparing explants and primary cells to t=0 as the same 282	
biopsy could be utilised in matched experiments and these 2 groups most closely resembled 283	
t=0 based on the microarray results. A separate set of biopsies obtained from non-labouring 284	
women were divided into (i) t=0, (ii) myometrial explants and (iii) primary cells, and utilised 285	
to assess key nuclear receptor levels on the protein level. Although the level of both PR 286	
isoforms tended to decline, there was no significant difference between t=0 and explants. 287	
However, the levels of PR were observed to be significantly lower in primary cells at passage 288	
4 than in either t=0 tissue or explants (Fig. 2A&B). The PR-A:PR-B ratio was similar in 289	
explants and cells although this was significantly raised compared to t=0 (p=0.0327 and 290	
p=0.0067 respectively) (Fig. 2C). No difference was observed in GR levels between t=0, 291	
explants and cells (Fig. 2A&D).  292	
 293	
Progesterone-repression of IL-1β-induced COX-2  294	
Previous group data demonstrated that 10µM was the minimum P4 dose causing a significant 295	
reduction in IL-1β-driven COX-2 in primary cells. Based on dose response experiments, the 296	
myometrial explant IL-1β EC50 was defined as 10ng/mL and the P4 IC50 P4 was 1µM 297	
(Suppl. Fig. 1).  298	
In order to directly compare P4 sensitivity, explants and cells originating from the same 299	
biopsy were treated with 10ng/mL IL-1β ± 1 or 10µM P4. Compared t=0, basal COX-2 levels 300	
were significantly raised in explants (p=0.0313) and not in cells. Although not significant, the 301	
addition of IL-1β showed a trend towards a greater increase in COX-2 levels in primary cells 302	
than in explants (p=0.07, Fig. 3). The IL-1β-induced increase in COX-2 protein levels was 303	
reduced by pre-incubation with 1µM P4 in myometrial explants and 10µM P4 in cell cultures 304	
(Fig. 3). 305	
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 306	
P4 acts via PR in myometrial explants and represses IL-1β-induced activation of p65 307	
and AP-1 308	
The mixed PR/GR antagonist RU486 reversed the repressive effect of 1µM P4 on IL-1β-309	
induced COX-2 expression in myometrial explants (Fig. 4). The more PR-selective inhibitor 310	
ZK299 at the PR-specific dose of 1µM (Kohmura et al. , 2000), also reversed the P4 effect 311	
(Fig. 4).  312	
IL-1β increased the phosphorylation of ERK (p=0.0156) and p38 (p=0.0313) as well as the 313	
transcription factor targets c-Jun (p=0.0078) and p65 (p=0.0078, Fig.4). Although a trend was 314	
observed, IL-1β did not significantly increase the phosphorylation of JNK or c-Fos (Fig. 5). 315	
Pre-incubation with 1µM P4 reduced the IL-1β induced increase in p65 and c-Jun 316	
phosphorylation, but interestingly, there was no reduction in MAPK phosphorylation, nor any 317	
change in MKP-1 or IκB levels following P4 treatment alone or in combination with IL-1β 318	
(Fig. 5). P4 treatment alone did not drive the MAPKs, c-Jun or p65 phosphorylation, but did 319	
lead to an increase in c-Fos phosphorylation (Fig. 5). 320	
 321	
Lack of a functional withdrawal of myometrial P4 action  322	
In order to determine whether there was any evidence of a functional P4 withdrawal with the 323	
onset of labour, we obtained myometrium from women before the onset of labour, in early 324	
labour ( < 3cm, termed the “latent phase” of labour), during which the cervix effaces, begins 325	
to dilate and contractions become regular and strong, and in established labour (> 3cms, 326	
termed the “active phase” of labour), during which the cervix dilates more rapidly and 327	
contractions are regular and strong. The increase in COX-2 levels induced by IL-1β was 328	
similar in all 3 groups (Suppl. Fig. 2). Pre-treatment of the explants with 1µM P4, was able to 329	
reduce the expression of IL-1β-driven COX-2 in all 3 groups (Fig. 6). Treatment with P4 330	
alone was not associated with a significant change in COX-2 levels compared to control (Fig. 331	
6). 332	
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The role of P4 was further studied by quantification of a panel of pro-inflammatory cytokines 333	
in the tissue culture media of explants obtained from non-labouring women as well as women 334	
in early and established labour. In the first instance, using non-labouring samples, we sought 335	
to identify which cytokines were driven by IL-1β in our model and, if so, whether P4 was 336	
able to significantly reduce these levels. We identified a shortlist of cytokines comprised of 337	
CXCL2, IL-6 and IL-8 (Fig. 7A-C).  338	
Next we determined whether the effect of IL-1β was altered by labour status by calculating 339	
the delta change (Δ) between control and IL-1β treated samples. As with COX-2, we found 340	
that the effect of IL-1β was similar in all 3 groups for CXL2, IL-6 and IL-8 (Fig. 7D-F). We 341	
then assessed whether P4 treatment alone altered the release of pro-inflammatory cytokines 342	
into the medium in either of the labouring groups and found that P4 had no effect on cytokine 343	
levels (Fig. 7A-C). Finally, we confirmed that there was no difference in the ability of P4 to 344	
repress IL-1β-induced increase in of CXCL2, IL-6 and IL-8 levels in the labouring samples 345	
(Fig. 7G-I).  346	
 347	
Discussion 348	
In this study, we sought to establish a model that reflects the in vivo situation more accurately 349	
than the current in vitro cell models and to use this model to study P4 signalling in the 350	
myometrium.  351	
We demonstrated that the explant transcriptome most closely resembles that of the in vivo 352	
(t=0) condition as compared to both myometrial cells and the hTERT cell line. Importantly, 353	
this pattern was preserved on examining genes relevant to reproductive function and 354	
parturition; for example the explant levels of PR (PGR), oxytocin receptor (OXTR) and 355	
connexin-43 (GJA1) did not vary significantly compared to t=0 (Table III). In contrast, PR 356	
RNA levels were significantly lower in both primary cells and hTERT. Indeed, the same 357	
pattern was observed for PR on the protein level with no significant change in explants versus 358	
t=0, but a significant reduction in primary cells. In addition, OXTR and GJA1 RNA levels 359	
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were significantly lower and higher respectively in primary cells (Table III). COX-2 (PTGS2) 360	
levels were significantly elevated in explants as well as hTERT, although upon comparing 361	
this upregulation in relation to COX-2 levels after IL-1β treatment, the effect was negligible 362	
with a signal-to-noise ratio of 17.7 (FDA, 2003). Indeed, it was noted that genes associated 363	
with inflammation were elevated in all 3 models as evidenced by gene ontology analysis 364	
(Suppl. Table I). We also determined that the expression pattern of smooth muscle markers 365	
such as alpha smooth muscle actin (ACTA2) and myosin light chain kinase (MYLK) remained 366	
unaltered in explants whereas both were significantly reduced in hTERT (Table III).  367	
We noted with interest that the uniquely upregulated genes in the explant group comprised 368	
glucose metabolism pathways (Suppl. Table II). We hypothesised that this was the result of 369	
the explants being cultured in DMEM without any additional nutrient supplementation and 370	
hence utilizing alternative biochemical pathways to produce glucose. As these pathways do 371	
not relate to reproduction, we feel they are not of great importance to the model. In an attempt 372	
to mimic the physiological conditions as closely as possible, we did supplement culture media 373	
with  P4, estradiol and/or the cAMP agonist forskolin, but found that this had no effect on 374	
restoring PR levels even closer to t=0 and hence these conditions were not incorporated into 375	
the final experimental model used (data not shown). 376	
One possible limitation of this transcriptome analysis was that it was conducted via 377	
microarray and not RNA-Seq, the latter being widely accepted as a superior platform with 378	
better concordance with quantitative RT-PCR (Wang et al. , 2014). However, the two share 379	
high correlation and for the purpose of this study, microarray was deemed appropriate. One 380	
notable case of poor concordance between microarray and quantitative RT-PCR data was GR 381	
(NR3C1), where the microarray indicated upregulation in all 3 models whereas quantitative 382	
RT-PCR showed downregulation (Table III). We sought to clarify our findings by 383	
undertaking protein level analysis and confirmed that GR levels do not vary significantly in 384	
explants or primary cells compared to t=0. 385	
On the protein level, we demonstrated that the treatment of explants with 1µM P4 386	
significantly reduces inflammation, whereas in myometrial cells it does not. Intriguingly, this 387	
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occurs despite the fact that the PR-A:PR-B ratio increases in explant culture versus snap 388	
frozen tissue. Interestingly, the response to IL-1β is greater in cultured myometrial cells with 389	
no evidence of increased sensitivity to P4 treatment, suggesting that explants do not just differ 390	
to myometrial cells in their cellular organization, but also in their overall sensitivity to 391	
different treatments.  392	
Even though other studies have shown that passaging of primary cells does not affect the 393	
myometrial phenotype (Mosher et al., 2013), our data suggest that there are marked 394	
functional differences between explants and primary cell cultures. Explants contain a 395	
heterogeneous collection of cell types, although smooth muscle cells predominate as shown 396	
by immunohistochemistry for alpha smooth muscle actin (data not shown); additionally they 397	
contract spontaneously and after treatment with oxytocin (data not shown).  398	
We have shown that both RU486 and ZK299 are capable of reversing the effect of P4. 399	
Although neither drug is a pure PR antagonist (Miner et al. , 2003), 1µM ZK299 has 400	
previously been shown to reverse the effect of P4 but not that of dexamethasone (Kohmura et 401	
al., 2000), suggesting that P4, in contrast to our observations from primary cell cultures (Lei 402	
et al., 2012), may signal via PR in explants. The reason for this may lie in the difference in 403	
nuclear receptor levels in the two models, with the explant model more closely resembling the 404	
in vivo state. Trial of other ‘specific’ PR and GR antagonists demonstrated that they have 405	
non-specific actions in myometrial explants (data not shown).  406	
In support of previous findings (Hardy et al., 2006), we show that P4 is able to repress the IL-407	
1β-induced activation of two major pro-inflammatory transcription factors: NF-κB and AP-1. 408	
Both of these transcription factors have previously been shown to be required for IL-1β-409	
mediated upregulation of COX-2 in gestational tissues (Allport et al. , 2000). However, the 410	
mechanism of P4 action does not appear to be via an increase in IκB as has previously been 411	
suggested (Hardy et al., 2006). Further, the reduction in c-Jun phosphorylation does not seem 412	
to be mediated via an increase in MKP-1 (Lei et al., 2015). It is possible that total c-Jun levels 413	
are reduced by P4 treatment or that other phosphatases are increased. These data further 414	
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demonstrate that the in vivo mechanism of P4 action may differ markedly compared to the in 415	
vitro models. 416	
Our data indicate that with the onset of labour, P4 does not become pro-inflammatory as 417	
suggested by other groups (Allport et al., 2000, Tan et al., 2012), nor does it lose its anti-418	
inflammatory action. Furthermore, the explant sensitivity to IL-1β does not alter with labour 419	
status, nor does the ability of P4 to down-regulate the IL-1β response suggesting that there is 420	
no functional withdrawal of P4 action, at least in terms of the ability of P4 to repress 421	
inflammation. However, it remains possible that there is a withdrawal of other P4-mediated 422	
functions that lead to the onset of labour. 423	
In conclusion, this study has established the validity of using an explant model to study 424	
myometrial P4 signalling. We provide evidence that P4 acts via PR to reduce IL-1β-induced 425	
COX-2 synthesis in associated with a reduction in NF-κB and AP-1 activation. Further, we 426	
show that P4 is able to repress IL-1β-induced gene expression even after the onset of labour, 427	
suggesting that, at least in this regard, there is no functional withdrawal of P4 action. 428	
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 538	
Figure 1. The myometrial explant transcriptome most closely resembles the 539	
physiological status.  Myometrial tissue obtained from term non-labouring women was snap 540	
frozen at the time Caesarean section (t=0), finely dissected into 3x3x3mm3 explants or 541	
digested with a collagenase mixture to isolate cells for primary culture. Explants were 542	
cultured in DMEM without treatment for 30 hours. After serum-starvation with 1% DCC-543	
FCS overnight, the media of myometrial cells at passage 4 and hTERT cells was refreshed 544	
and cells incubated  for a further 30 hours without treatment. RNA was extracted as described 545	
in Methods. Whole-genome transcriptome analysis was conducted by hybridization to 546	
Affymetrix Human Gene 2.1 ST array strips and analysed using Partek Genomics Suite 6.6 547	
software. Differentially expressed genes (DEG) were identified by two-way ANOVA, and p-548	
values were adjusted using the FDR (false-discovery rate) method to correct for multiple 549	
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comparisons. DEG were considered significant if p-value was p≤0.05 at a fold change of >2 550	
with FDR <0.5. n=6. A. PCA plot. B. Venn diagram of genes varying significantly versus t=0 551	
which are common and unique to each model. C. Volcano plot of myometrial explants. D. 552	
Volcano plot of primary cells. E. Volcano plot of hTERT.  553	
 554	
Figure 2. Myometrial explants maintain nuclear receptor levels in culture. Myometrial 555	
tissue obtained from term non-labouring women was snap frozen, finely dissected into 556	
3x3x3mm3 explants or digested with a collagenase mixture to isolate the cells for primary 557	
culture. Explants were treated immediately with ethanol vehicle for 30 hours. After serum-558	
starvation with 1% DCC-FCS overnight, primary cells at passage 4 were treated with ethanol 559	
vehicle for 30 hours. Protein was extracted and quantified. Western blotting for the 560	
progesterone receptor (PR) isoforms (PR-A and PR-B) and glucocorticoid receptor (GR) was 561	
performed as described in Methods. A. Representative western blot of PR and GR levels B. 562	
Densitometric analysis of PR levels. C. Analysis of PR-A:PR-B ratio D. Densitometric 563	
analysis of GR levels. The data are expressed as mean + SEM. Normality was tested using a 564	
Shapiro-Wilks test followed by Wilcoxon signed rank testing. #, p<0.05 cells vs explants for 565	
PR-B; ##, p<0.01 cells vs t=0 for PR-B; *, p<0.05 cells vs explants for PR-A; **, p<0.01 566	
cells vs t=0 for PR-A; $, p<0.05 t=0 vs explants; $$, p<0.01 t=0 vs cells. n=8-9. 567	
 568	
Figure 3. Explants respond to 1µM progesterone (P4) in paired biopsies whereas 569	
myometrial cells do not. Myometrial tissue obtained from term non-labouring women was 570	
snap frozen, finely dissected into 3x3x3mm3 explants or digested with a collagenase mixture 571	
to isolate cells for primary culture. Explants were immediately pre-treated for 6 hours with 572	
ethanol vehicle, 1µM P4 or 10µM P4 followed by a 24 hour treatment with IL-1β (10ng/mL).  573	
After serum-starvation with 1% DCC-FCS overnight, primary cells at passage 4 were pre-574	
treated for 6 hours with ethanol vehicle, 1µM P4 or 10µM P4 followed by a 24 hour treatment 575	
with IL-1β (10ng/mL). Protein was extracted and quantified. Western blotting for 576	
cyclooxygenase-2 (COX-2) was performed as described in Methods. A representative western 577	
22		
 	
blot is shown at the top of the figure with densitometric analysis below. The data are 578	
expressed as mean + SEM. Normality was tested using a Kolmogorov-Smirnov test followed 579	
by comparison of control versus IL-1β by Wilcoxon signed rank testing or paired t testing 580	
depending on the data distribution; *, p<0.05 versus control in that group; $, p<0.05 versus 581	
t=0. The IL-1β, 1µM P4 & IL-1β and 10µM P4 & IL-1β conditions in each group were 582	
compared by ANOVA followed by Bonferroni’s Multiple Comparison Test; #, p<0.05 versus 583	
IL-1β in that group; ##, p<0.01 versus IL-1β in that group. n=4-8. 584	
 585	
Figure 4. Mifepristone (RU486) and onapristone (ZK299) reverse the progesterone (P4) 586	
-mediated reduction in IL-1β-driven cyclooxygenase-2 (COX-2) in myometrial explants. 587	
Myometrial tissue obtained from term non-labouring women was finely dissected into 588	
3x3x3mm3 explants. These were immediately pre-treated for 6 hours with ethanol & DMSO 589	
vehicle, 1µM P4 ± 1µM RU486 or 1µM ZK299 followed by a 24 hour treatment with IL-1β 590	
(10ng/mL).  Protein was extracted and quantified. Western blotting for COX-2 was performed 591	
as described in Methods. A representative western blot is shown at the top of the figure with 592	
densitometric analysis below. The data are expressed as mean + SEM. Normality was tested 593	
using a Kolmogorov-Smirnov test. Paired t tests were used to compare control versus IL-1β 594	
(*, p<0.05) and IL-1β versus P4 & IL-1β (#, p<0.05). The shaded groups were compared with 595	
a Friedman test followed by Dunn’s Multiple Comparison Test; $, p<0.05; $$, p<0.01. n=6-7. 596	
 597	
Figure 5. Progesterone (P4) reduces the phosphorylation of pro-inflammatory 598	
transcription factors in myometrial explants. Myometrial tissue obtained from term non-599	
labouring women was finely dissected into 3x3x3mm3 explants. These were immediately pre-600	
treated for 6 hours with ethanol or 1µM P4 followed by a 30 minute treatment with IL-1β 601	
(10ng/mL).  Protein was extracted and quantified, and Western blotting for A. p-ERK1/2, B. 602	
p-p38, C. p-JNK, D. p-c-Jun, E. p-c-Fos, F. MKP-1, G. p-p65 and H. IκB was performed as 603	
described in Methods. A representative Western blot is shown at the top of each figure with 604	
densitometric analysis below. The data are normalised to control and expressed as mean + 605	
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SEM. Normality was tested using a Kolmogorov-Smirnov for 6 replicates or a Shapiro-Wilk 606	
test for more than 6 replicates. Wilcoxon signed rank testing was used to compare between 607	
pairs; *, p<0.05 versus control; **, p<0.01 versus control; #, p<0.05 versus IL-1β; ##, p<0.01 608	
versus IL-1β. n=6-8. 609	
 610	
Figure 6. Progesterone (P4) maintains its anti-inflammatory role throughout labour. 611	
Myometrial tissue obtained from women in term A. early labour and B. established labour 612	
was finely dissected into 3x3x3mm3 explants. These were immediately pre-treated for 6 hours 613	
with ethanol vehicle or 1µM P4 followed by a 24 hour treatment with IL-1β (10ng/mL).  614	
Protein was extracted and quantified. Western blotting for cyclooxygenase-2 (COX-2) was 615	
performed as described in Methods. A representative western blot is shown at the top of each 616	
figure with densitometric analysis below. The data are expressed as mean + SEM. Normality 617	
was tested using a Shapiro-Wilk test. A Wilcoxon signed rank test was used for non-normally 618	
distributed data and a paired t test for normally distributed data. **, p<0.01 versus control; 619	
***, p<0.001 versus control; #, p<0.05 versus IL-1β. n=8. 620	
 621	
Figure 7. Progesterone does not become pro-inflammatory with labour onset and it 622	
reduces the expression of proinflammatory cytokines/chemokines irrespective of labour 623	
status. The media from explant cultures was used to run human Bio-Plex© ProTM 624	
chemokine/cytokine assays for A, D, G. CXCL2, B, E, H. IL-6 and C, F, I. IL-8  as per the 625	
manufacturer’s protocol. Data were normalised to tissue weight. The data in panels A-C are 626	
standardised to control and expressed as mean + SEM. The data in panels D-F are expressed 627	
as mean + SEM of the delta (Δ) between IL-1β and control groups. The data in panels E-I  are 628	
standardised to IL-1β and expressed as mean + SEM.  Normality was tested using a 629	
Kolmogorov-Smirnov for 6 replicates or a Shapiro-Wilk test for more than 6 replicates. For 630	
groups of 3, a Kruskal Wallis test was performed followed by Dunn’s Multiple Comparison 631	
Test for non-normally distributed data and an ANOVA followed by Bonferroni’s Multiple 632	
Comparison Test was performed for normally distributed data. Wilcoxon matched pair testing 633	
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was used for non-normally distributed paired data and paired t tests for normally distributed 634	
data. For comparisons to vehicle control within matched labour status group, statistical 635	
significance is indicated as follows: *, p<0.05; **, p<0.01; ***, p<0.001. For comparisons to 636	
IL-1β within matched labour status group, statistical significance is indicated as follows: #, 637	
p< 0.05;  ##, p<0.01; ###, p<0.001. n=6-16. Labour status groups are labelled as TNL (term 638	
no labour), TEaL (term early labour) and TEsL (term established labour). 639	
 640	
Supplementary Figure 1. Myometrial axplant dose response data for IL-1β and 641	
progesterone (P4). Myometrial tissue obtained from term non-labouring women was finely 642	
dissected into 3x3x3mm3 explants. These were immediately pre-treated for 6 hours with 643	
ethanol followed by a 24 hour treatment with IL-1β (1, 10, 20, 50 or 100ng/mL) (A). 644	
Alternatively, explants were immediately pre-treated for 6 hours with ethanol or various P4 645	
doses (0.1, 0.5, 1, 5 or 10µM) followed by a 24 hour treatment with IL-1β (10ng/mL) (Panel 646	
B). Protein was extracted and quantified. Western blotting for cyclooxygenase-2 (COX-2). 647	
was performed as described in Methods. A representative western blot is shown at the top of 648	
each figure with densitometric analysis below. The data are expressed as mean + SEM. 649	
Normality was tested a Shapiro-Wilk test. Wilcoxon signed rank test was used for non-650	
normally distributed data and a paired t test for normally distributed data; *, p<0.05 versus 651	
control;; #, p<0.05 versus IL-1β; ##, p<0.01 versus IL-1β. n=8. 652	
 653	
Supplementary Figure 2. The effect of IL-1β on cyclooxygenase-2 (COX-2) does not 654	
alter with labour status in the myometrium. Myometrial tissue obtained from women not 655	
in labour at term as well as in term early and established labour was finely dissected into 656	
3x3x3mm3 explants. These were immediately pre-treated for 6 hours with ethanol vehicle or 657	
1µM P4 followed by a 24 hour treatment with IL-1β (10ng/mL).  Protein was extracted and 658	
quantified. Western blotting for cyclooxygenase-2 (COX-2) was performed as described in 659	
Methods. The data are expressed as mean + SEM of the delta (Δ) between IL-1β and control 660	
groups. Normality was tested using a Kolmogorov-Smirnov test followed by an ANOVA 661	
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with Bonferroni’s Multiple Comparison Test. n=6-8. Labour status groups are labelled as 662	
TNL (term no labour), TEaL (term early labour) and TEsL (term established labour). 663	
